<DOC>
	<DOCNO>NCT01828619</DOCNO>
	<brief_summary>The purpose study determine whether new RIC regimen , contain low dose Bu ( 9.6mg/kg ) fludarabine without ATG , suitable effective treat age and/or intolerable patient hematologic malignant disease , undergoes allogenic stem cell transplantation .</brief_summary>
	<brief_title>Study New RIC Regimen BuFlu Older and/or Intolerable Patients</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>diagnose hematologic malignant disease undergo HLA matced HSCT age &gt; =55years &lt; 55year intolerable standard myeloablative conditioning KPS status &lt; 70 cardiac EF &lt; 50 % creatine clearance &lt; 50 ml/min ALT 10 time upper normal limit</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabine</keyword>
</DOC>